<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04179487</url>
  </required_header>
  <id_info>
    <org_study_id>01</org_study_id>
    <nct_id>NCT04179487</nct_id>
  </id_info>
  <brief_title>The OPTICA Study - The Optimised Computed Tomography Pulmonary Angiography (CTPA) in Pregnancy, Quality and Safety Study</brief_title>
  <acronym>OPTICA</acronym>
  <official_title>The OPTICA Study - A Prospective Study Assessing the Quality and Safety of an Optimised CTPA Protocol in Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College Dublin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mater Misericordiae University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University College Dublin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective multicentre study aiming to validate the clinical utility and safety of an
      optimised low-dose computed-tomography pulmonary angiogram (CTPA) protocol for suspected
      pulmonary embolism in pregnancy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The OPTICA study is the first prospective study of a low-dose CTPA protocol for the pregnant
      population. It will define the achievable dose, image quality and safety of this protocol and
      provide an evidence base upon which modern CTPA protocols can be appropriately compared to
      scintigraphy for this population.

      Pregnant women undergoing the specified low-dose CTPA protocol for suspected pulmonary
      embolism (PE), agreed across study sites with equivalent computed-tomography (CT)
      capabilities, will be included. Independent review of CTPAs by two radiology consultants,
      image data analysis and 3-month patient follow up will be performed.

      The diagnostic algorithm employs chest-x-ray and lower limb Doppler if lower limb symptoms
      are present, followed by CTPA in cases where advanced imaging is required. D-dimer is
      permitted within the diagnostic algorithm for patients recruited after implementation of the
      updated 2019 &quot;European Society of Cardiology guidelines for diagnosis and management of acute
      pulmonary embolism&quot;.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 29, 2018</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Venous Thrombo-Embolism (VTE)</measure>
    <time_frame>3 months</time_frame>
    <description>3-month incidence of venous thromboembolism in pregnant patients in whom pulmonary embolism was excluded at baseline CT pulmonary angiogram.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maternal Effective Dose</measure>
    <time_frame>3 months</time_frame>
    <description>Maternal Effective Dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breast Radiation Dose</measure>
    <time_frame>3 months</time_frame>
    <description>Breast Dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Foetal Radiation Dose</measure>
    <time_frame>3 months</time_frame>
    <description>Foetal (Uterine) Dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Signal to Noise Ratio</measure>
    <time_frame>3 months</time_frame>
    <description>Image Quality - Objective Variable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast to Noise Ratio</measure>
    <time_frame>3 months</time_frame>
    <description>Image Quality - Objective Variable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Pulmonary Trunk Enhancement</measure>
    <time_frame>3 months</time_frame>
    <description>Image Quality - Objective Variable (Hounsfield Units)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Imaging Quality Grade</measure>
    <time_frame>3 months</time_frame>
    <description>Subjective Imaging Quality Score: Score 1 - 5. Lowest score of 1 indicates a non diagnostic quality study. Best score of 5 indicates excellent quality / excellent opacification to the segmental pulmonary vessel level.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">464</enrollment>
  <condition>Pulmonary Embolism</condition>
  <condition>Pregnancy Related</condition>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Pregnant Patients with Suspected PE</arm_group_label>
    <description>Pregnant Patients with Suspected pulmonary embolism undergoing low dose CT pulmonary angiogram</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>OPTICA CTPA Protocol</intervention_name>
    <description>Low dose CT pulmonary angiogram protocol</description>
    <arm_group_label>Pregnant Patients with Suspected PE</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant Patients with Suspected pulmonary embolism
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pregnant patients with a suspected pulmonary embolism

          2. Ageâ‰¥18 years

        Exclusion Criteria:

          1. Age &lt; 18 years

          2. Ultrasound proof of symptomatic proximal deep vein thrombosis

          3. Contraindication to helical CT because of allergy to intravenous iodinated contrast or
             renal insufficiency (creatinine clearance &lt;30 ml/min)

          4. Treatment with full-dose therapeutic low molecular weight heparin or unfractionated
             heparin initiated 24 h or more prior to eligibility assessment

          5. Treatment with vitamin K antagonists (coumarin derivates i.e. warfarin)

          6. Unable or unwilling to consent

          7. Unable to part-take in follow-up

          8. Life expectancy &lt;3 months
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ciara Gillespie, MB BCH BAO</last_name>
    <phone>+353 1 8032000</phone>
    <phone_ext>4230</phone_ext>
    <email>ciaragillespie@mater.ie</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peter MacMahon, MB BCH BAO</last_name>
    <phone>+353 1 8032000</phone>
    <email>pmacmahon@mater.ie</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mater Misericordiae University Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>D07R2WY</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ciara Gillespie, MB BCH BAO</last_name>
      <email>ciaragillespie@mater.ie</email>
    </contact>
    <contact_backup>
      <last_name>Peter MacMahon, MB BCH BAO</last_name>
      <email>pmacmahon@mater.ie</email>
    </contact_backup>
    <investigator>
      <last_name>Peter MacMahon, MB BCH BAO</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fionnuala NiAinle, MB BCH BAO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <reference>
    <citation>Gillespie C, Foley S, Rowan M, Ewins K, NiAinle F, MacMahon P. The OPTICA study (Optimised Computed Tomography Pulmonary Angiography in Pregnancy Quality and Safety study): Rationale and design of a prospective trial assessing the quality and safety of an optimised CTPA protocol in pregnancy. Thromb Res. 2019 May;177:172-179. doi: 10.1016/j.thromres.2019.03.007. Epub 2019 Mar 13.</citation>
    <PMID>30921536</PMID>
  </reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 25, 2019</study_first_submitted>
  <study_first_submitted_qc>November 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2019</study_first_posted>
  <last_update_submitted>November 26, 2019</last_update_submitted>
  <last_update_submitted_qc>November 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mater Misericordiae University Hospital</investigator_affiliation>
    <investigator_full_name>Peter MacMahon</investigator_full_name>
    <investigator_title>Professor Peter J Mac Mahon, MB BCH BAO, BMedSci, MRCPI, FFRRCSI.</investigator_title>
  </responsible_party>
  <keyword>pulmonary embolism</keyword>
  <keyword>pregnancy</keyword>
  <keyword>tomography xray computed</keyword>
  <keyword>radiation dosage</keyword>
  <keyword>negative predictive value</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

